格隆汇9月5日丨富祥药业(300497.SZ)于近期投资者关系活动表示，公司三氮唑新工艺他唑巴坦产品顺 利完成下游客户合格供应商备案，产品产能有望释放，将不仅能够降低他唑巴坦产品生产成本，同时还 能提高产品售价及市场竞争力。 ...

Core Viewpoint - Fuxiang Pharmaceutical is experiencing a growth in its mid-year performance compared to last year, but it remains in a loss position. The company plans to improve its net profit through various products and strategies [2]. Group 1: Business Performance and Strategies - The company aims to enhance its pharmaceutical business by increasing the selling price of key intermediates and expanding production capacity for various products, which will improve gross margins and competitiveness [2]. - In the new energy sector, Fuxiang's lithium battery electrolyte additive products are performing well in terms of shipment volume and cost control, with prices at historical lows, indicating potential for profit growth as the industry recovers [2]. - The synthetic biology sector is being developed with a focus on microbial protein, with a new food raw material application already accepted for review by the National Health Commission, aiming for approval and market launch in the second half of the year [2][4]. Group 2: Microbial Protein Business Advantages - Fuxiang Pharmaceutical is a pioneer in the domestic microbial protein industry, with significant production capacity and proprietary technology, including patents in multiple countries [3]. - The company has achieved international advanced levels in key technologies for microbial protein production and has received various quality certifications for its products [3]. - Collaborations with academic institutions are in place to foster innovation across the entire industry chain, emphasizing green production and cost efficiency [3]. Group 3: Future Plans for Synthetic Biology - The company plans to obtain necessary approvals for its new protein products and enhance market presence through brand building and international expansion [4]. - Focus will be on accelerating the industrialization of new protein products and recruiting talent to build a high-performance team [4]. - Strategic partnerships have been established to advance product development and market promotion, with a strong outlook for amino acid water-soluble fertilizers [4].

Financial Performance - The company reported an increase in mid-year performance compared to last year, but remains in a loss state [2] - Future strategies will focus on improving net profit through various products and avenues [2] Pharmaceutical Manufacturing - The decline in raw material prices for 6-APA and the recovery in prices for the key intermediate 4-AA will enhance the gross margin of the pharmaceutical business [3] - Successful completion of supplier qualification for the new process product, Tazobactam, is expected to reduce production costs and improve market competitiveness [3] - Expansion of Piperacillin production capacity is underway, with significant market demand for combination formulations [3] - New compound formulations are being launched, which will drive demand for related products [3] New Energy Business - The company leads in the industry for lithium battery electrolyte additives in terms of shipment volume and cost control [3] - Current prices for these additives are at historical lows, with limited room for further decline; a price rebound could significantly enhance profits [3] Synthetic Biology - The company is a pioneer in microbial protein production, with significant advancements in core strains, production technology, and market access [4][5] - The registration application for the new protein as a food ingredient has been accepted, with expectations for approval in the second half of the year [4][9] - The company is constructing a project with an annual capacity of 200,000 tons of microbial protein, aiming for a production scale of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer [5][15] Quality and Certification - The new protein has received multiple international certifications, including HALAL and KOSHER, and has passed various food safety management system certifications [6] - The company has developed proprietary strains and achieved international advanced levels in production technology [5][6] Market Expansion and Collaboration - Strategic partnerships have been established with various companies in the microbial protein sector, enhancing market penetration [11] - The company plans to build an open commercial transformation platform to accelerate product commercialization and brand development [10] Product Development - The new protein can be applied in various sectors, including plant-based meat alternatives, protein drinks, and health products [12] - The company is actively developing new applications and has created several product samples for market introduction [12] Environmental and Regulatory Compliance - The company’s production processes aim for zero emissions and align with national agricultural reduction goals [7][14] - The amino acid water-soluble fertilizer is positioned to meet growing market demands due to regulatory support for green products [15]

Group 1 - The plant-based meat concept index rose by 1.67%, ranking 8th among concept sectors, with 18 stocks increasing in value [1][2] - Leading stocks in the plant-based meat sector included SuoBao Protein, LingGe Technology, and HaiXin Food, which rose by 7.15%, 6.71%, and 4.42% respectively [1][2] - The sector experienced a net inflow of 0.14 billion yuan, with nine stocks receiving net inflows, led by SuoBao Protein with a net inflow of 28.15 million yuan [2][3] Group 2 - The top net inflow ratios in the plant-based meat sector were SuoBao Protein at 8.52%, JiaHua Co. at 7.55%, and FuXiang Pharmaceutical at 7.10% [3][4] - The trading volume for SuoBao Protein was 16.09%, while other notable stocks included AnQi Yeast and FuXiang Pharmaceutical with trading volumes of 1.03% and 3.10% respectively [3][4] - Stocks that saw declines included GuoEn Co. and XueRong Biological, which fell by 3.09% and 0.83% respectively [1][4]

Group 1 - The company, Fuxiang Pharmaceutical, announced the cancellation of 11,355,900 shares, which represents 2.06% of the total shares before cancellation [2] - The total amount for the share repurchase cancellation was RMB 174,830,966 [2] - Following the cancellation, the company's total share capital decreased from 550,004,834 shares to 538,648,934 shares [2]

证券代码：300497 证券简称：富祥药业 公告编号：2025-061 江西富祥药业股份有限公司 关于公司控股股东、实际控制人及其一致行动人权益变动触及1%整 数倍的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 本次权益变动的主要原因系： 1、江西富祥药业股份有限公司（以下简称"公司"）于2024年2月1日披露了《关 于公司控股股东、实际控制人、董事长及副董事长、高级管理人员增持公司股份计划 的公告》（公告编号：2024-008），公司控股股东、实际控制人、董事长包建华先生 计划自本公告披露之日起6个月内，通过集中竞价或法律法规允许的其他方式增持公 司股票，增持金额不低于2,500万元且不超过5,000万元。包建华先生于2024年4月29日 -2024年5月6日，通过集中竞价方式累计增持235.01万股，占公司总股本比例0.43%， 增持金额为2,513.04万元。 2、公司于2025年6月27日召开第四届董事会第二十八次会议、第四届监事会第十 八次会议，于2025年7月14日召开2025年第二次临时股东大会，审议通过了《关于变 更回购股份 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-060 江西富祥药业股份有限公司 关于回购股份注销完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、江西富祥药业股份有限公司（以下简称"公司"）本次注销的回购股份数量 为11,355,900股，占注销前公司总股本的比例为2.06%，回购注销金额为人民币 174,830,966元；本次回购注销完成后，公司总股本由550,004,834股减少为538,648,934 股。 2、公司于2025年9月2日在中国证券登记结算有限责任公司深圳分公司办理完成 上述11,355,900股回购股份的注销手续，后续将依据相关规定在市场监督管理局办理 变更登记及章程备案等相关事宜。 根据《中华人民共和国公司法》《上市公司股份回购规则》《深圳证券交易所上 市公司自律监管指引第9号——回购股份》等有关规定，现将本次回购股份注销完成 情况公告如下： 一、回购股份概述 公司于2021年8月4日召开第三届董事会第二十四次会议，审议通过了《关于回购 公司股份方案的议案》，决定使用不低于人民币1亿元 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-059 为满足公司战略发展需要，加快拓展微生物蛋白业务市场，公司拟使用自有资金 出资在新加坡设立富祥微生物蛋白应用消费产品开发及销售子公司，注册资本为不超 过300万新加坡元。具体内容详见公司在巨潮资讯网上披露的《关于拟设立子公司的 公告》（公告编号：2024-084）。 二、对外投资进展情况 公司已于近日完成了新加坡全资子公司的注册登记手续，并取得了当地主管部门 签发的注册登记证明文件，具体信息如下： 江西富祥药业股份有限公司 关于新加坡全资子公司完成注册登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资概述 注册登记证明文件。 特此公告。 江西富祥药业股份有限公司 董事会 | 公司名称 | FUNEXT INTERNATIONAL PTE.LTD（未冉国际实业有限公司） | | --- | --- | | 注册编号 | 202531620K | | 成立日期 | 2025年7月21日 | | 公司类型 | SHARES（股份有限公司） PRIVATE COMPANY LI ...

Group 1 - The core viewpoint of the article highlights the recognition of Peng Yun, the Secretary of the Board of Fuxiang Pharmaceutical, who won the 11th Golden Unicorn Award for Outstanding Secretary of the Board, reflecting his exceptional professional capabilities and performance [1][2] - The role of a Secretary of the Board is emphasized as a critical link between listed companies and the capital market, serving multiple functions such as a gatekeeper for corporate governance and a strategist for capital operations [1][2] - The Golden Unicorn Award has been held for eleven sessions, recognizing over 900 outstanding secretaries, and is regarded as a highly authoritative award in the industry, focusing on information disclosure quality and contributions to corporate governance and ESG [1] Group 2 - The article underscores the importance of effective communication by secretaries of the board in building trust between companies, investors, regulatory bodies, and the media, which is essential for long-term stable development [2] - Peng Yun is portrayed as a representative of excellence in the field, with the award reflecting both his individual capabilities and the high recognition of Fuxiang Pharmaceutical's governance and value growth by the market and investors [2]

Core Insights - Microbial protein is a promising exploration under the "Big Food" concept, with significant breakthroughs in recent years, including the approval of yeast protein as a new food ingredient and domestic leaders obtaining GRAS certification in the U.S. [1] - The market for microbial protein is projected to reach a scale of 60 billion yuan by 2035, driven by technological advancements and potential policy support for replacing traditional animal protein [2] Industry Overview - The demand for high-quality protein in China is rising, but there is a supply gap due to reliance on imported plant protein and limited capacity for animal protein. Microbial protein offers a balanced, efficient, and clean alternative, with commercial viability accelerating [1][2] - Microbial protein is categorized into two technological paths: biomass fermentation and precision fermentation. The former is more commercially mature, while the latter, which involves genetic editing, has higher technical difficulty but offers greater added value [2] Company Landscape - Entrepreneurial companies are leading in technological innovation, with examples like Quorn and Impossible Foods setting industry standards. In China, companies like Changjin Bio and Momi Bio are advancing rapidly, with several products nearing commercial production [3] - Traditional consumer goods and meat companies are entering the market through light-asset strategies, leveraging brand and channel advantages, as seen with Nestlé's collaboration with Perfect Day [3] - Major fermentation companies like Budweiser and Angel Yeast are building their own production capacities, benefiting from their accumulated industrial fermentation experience and knowledge [3] Competitive Dynamics - Technology is the core competitive factor across all stages of microbial protein development, influencing product development, regulatory approval, and cost-effective end products. Companies with strong financial backing and production capacity are expected to have a competitive edge [3]